Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs

Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00675207

Enrollment

120

Registered

2008-05-08

Start date

2006-01-31

Completion date

2007-07-31

Last updated

2008-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open Angle Glaucoma, Ocular Hypertension

Keywords

glaucoma, ocular hypertension, adjunctive treatment, prostaglandin, prostaglandin analog, brimonidine, dorzolamide, brinzolamide, alpha agonist, carbonic anhydrase inhibitor, intraocular pressure

Brief summary

The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.

Interventions

DRUGBrimonidine purite 0.15%

A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.

DRUGDorzolamide 2%

A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.

DRUGBrinzolamide 1%

A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

41 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of primary open-angle glaucoma or ocular hypertension. * Must be over 40 years of age. * Intraocular pressure must be 18 mm Hg or higher after 6 weeks of treatment (run-in) with a prostaglandin analog (bimatoprost, latanoprost, or travoprost).

Exclusion criteria

* History of angle closure or narrow angle. * Previous intraocular surgery. * Laser trabeculoplasty within 3 months prior to screening. * History of uveitis or intraocular inflammation. * Use of medications other than the study medications that are known to affect IOP (e.g., beta-blockers, steroids, or angiotensin II blockers) within 3 months of study entry or during the study. * Intolerance of or hypersensitivity to prostaglandin analogs, sulfonamides, alpha-agonists, or the preservative benzalkonium chloride. * Women of childbearing age who are pregnant or not using contraception.

Design outcomes

Primary

Measure	Time frame
Intraocular pressure	Measurements at peak and trough effect (10 am and 4 pm) at baseline, month 1, and month 4

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026